◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › S › SNY

Sanofi ADR (SNY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · DATA UPDATED 2026-09-09

Sanofi ADR (SNY) operates in the DRUG MANUFACTURERS - GENERAL industry and is headquartered in Paris, France with about 74,846 employees. Its market capitalization is roughly $102 billion. In the fiscal year ended 2025-12-31, SNY reported €46.7B in revenue and €7.8B in net income.

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.

Interactive charts & full statements → Open the SNY valuation workbench →

SNY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	€48.9B	€46.7B	€44.3B	€41.6B	€40.6B	€39.2B	€37.4B	€37.6B	€35.7B	€36.2B	€34.7B	€34.9B	€32.0B	€31.3B	€36.0B	€35.1B	€34.0B	€30.7B	€28.8B	€29.2B	€29.5B
Gross Profit	€35.7B	€33.7B	€31.1B	€29.0B	€28.7B	€26.9B	€25.2B	€25.7B	€24.2B	€24.6B	€24.0B	€23.9B	€21.8B	€21.0B	€24.9B	€24.2B	€24.6B	€22.9B	€21.5B	€21.6B	€21.9B
Gross Margin %	73.0%	72.1%	70.2%	69.7%	70.7%	68.7%	67.5%	68.2%	68.0%	67.9%	69.2%	68.7%	68.0%	67.1%	69.1%	69.0%	72.4%	74.4%	74.5%	74.1%	74.3%
Operating Income (EBIT)	€7.2B	€9.6B	€7.3B	€7.0B	€10.2B	€8.1B	€14.1B	€3.1B	€4.7B	€5.8B	€6.5B	€5.6B	€6.1B	€5.0B	€6.4B	€5.9B	€6.5B	€6.4B	€4.4B	€5.9B	€5.7B
Operating Margin %	14.8%	20.5%	16.4%	16.7%	25.1%	20.7%	37.8%	8.1%	13.1%	16.0%	18.8%	16.1%	18.9%	15.9%	17.9%	16.7%	19.2%	20.7%	15.2%	20.2%	19.4%
Net Income	€4.0B	€7.8B	€5.6B	€5.4B	€8.4B	€6.2B	€12.3B	€2.8B	€4.3B	€8.4B	€4.7B	€4.3B	€4.4B	€3.7B	€4.9B	€5.6B	€5.5B	€5.3B	€3.9B	€5.3B	€4.0B
Net Margin %	8.1%	16.7%	12.6%	13.0%	20.6%	15.9%	32.9%	7.3%	12.1%	23.2%	13.6%	12.3%	13.7%	11.9%	13.6%	16.1%	16.1%	17.1%	13.4%	18.0%	13.6%
EBITDA	€12.4B	€12.5B	€11.0B	€11.4B	€13.5B	€11.5B	€17.9B	€10.7B	€9.2B	€9.6B	€9.9B	€10.1B	€9.5B	€10.2B	€11.4B	€11.6B	€11.8B	€11.4B	€10.5B	€10.8B	€12.1B
Earnings Per Share (EPS)	€1.62	€3.20	€2.22	€2.15	€3.34	€2.48	€4.90	€2.19	€1.72	€3.35	€1.83	€1.64	€1.67	€1.40	€1.85	€2.14	€2.09	€2.01	€1.46	€1.94	€1.47
Shares Outstanding (M)	2,393M	2,441M	2,503M	2,513M	2,504M	2,505M	2,507M	1,257M	2,510M	2,514M	2,573M	2,612M	2,632M	2,646M	2,639M	2,643M	2,611M	2,613M	2,632M	2,708M	2,718M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	€12.3B	€11.2B	€12.2B	€13.2B	€10.7B	€10.6B	€7.6B	€14.2B
Gross Profit	€9.3B	€8.1B	€8.6B	€9.8B	€7.7B	€7.7B	€5.4B	€10.1B
Gross Margin %	75.5%	72.1%	70.3%	74.1%	72.1%	72.8%	70.2%	71.2%
Operating Income (EBIT)	€2.4B	€2.3B	(€1.0B)	€3.6B	€1.5B	€2.2B	€573M	€3.6B
Operating Margin %	19.4%	20.2%	-8.5%	27.5%	13.7%	21.1%	7.5%	25.7%
Net Income	€343M	€1.6B	(€801M)	€2.8B	€3.9B	€1.9B	€499M	€2.8B
Net Margin %	2.8%	14.3%	-6.6%	21.3%	36.7%	17.6%	6.5%	19.9%
EBITDA	€1.7B	€2.7B	€3.8B	€4.2B	€1.9B	€2.8B	€563M	€4.2B
Earnings Per Share (EPS)	€0.14	€0.67	€-0.33	€1.14	€1.60	€0.76	€0.20	€1.12
Shares Outstanding (M)	2,393M	2,408M	2,441M	2,468M	2,468M	2,468M	2,507M	2,506M

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	€14.3B	€12.1B	€9.1B	€10.3B	€10.5B	€10.5B	€7.4B	€7.7B	€5.5B	€7.4B	€7.8B	€8.9B	€7.7B	€7.0B	€8.2B	€9.3B	€9.8B	€8.5B	€8.5B	€7.1B	€6.6B
Capital Expenditures (CapEx)	€4.2B	€2.0B	€3.2B	€2.9B	€2.2B	€2.0B	€2.1B	€1.8B	€2.0B	€2.0B	€2.1B	€2.8B	€1.6B	€1.4B	€1.6B	€1.8B	€1.6B	€1.8B	€1.6B	€1.6B	€1.5B
Free Cash Flow (FCF)	€10.1B	€10.1B	€5.9B	€7.4B	€8.3B	€8.5B	€5.3B	€5.9B	€3.6B	€5.4B	€5.8B	€6.1B	€6.1B	€5.6B	€6.6B	€7.5B	€8.2B	€6.7B	€6.9B	€5.5B	€5.2B
FCF Margin %	20.6%	21.7%	13.3%	17.7%	20.5%	21.6%	14.3%	15.8%	10.0%	15.0%	16.6%	17.6%	19.2%	17.8%	18.2%	21.5%	24.1%	21.9%	24.0%	18.9%	17.5%
Dividends Paid	—	€5.4B	€4.7B	€4.5B	€4.2B	€4.0B	€3.9B	€3.8B	€3.8B	€3.7B	€3.8B	€3.7B	€3.7B	€3.6B	€3.5B	€1.4B	€3.1B	€2.9B	€2.7B	€2.4B	€2.0B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-09-30
Cash from Operations (CFO)	€5.4B	€1.7B	€3.4B	€3.8B	€1.5B	€2.1B	€3.8B
Capital Expenditures (CapEx)	€1.5B	€0M	€1.9B	€845M	€0M	€0M	€0M
Free Cash Flow (FCF)	€3.9B	€1.7B	€1.6B	€2.9B	€1.5B	€2.1B	€3.8B
FCF Margin %	31.7%	15.0%	13.0%	22.1%	13.6%	19.7%	27.2%
Dividends Paid	€5.7B	—	—	—	—	—	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

SNY Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	€129.1B	€126.8B	€132.8B	€126.5B	€126.7B	€120.2B	€114.4B	€112.6B	€111.4B	€99.8B	€104.7B	€102.3B	€97.4B	€96.1B	€100.4B	€100.7B	€85.3B	€80.0B	€72.0B	€69.0B	€74.3B
Cash & Cash Equivalents	€6.3B	€7.7B	€7.4B	€8.7B	€12.7B	€10.1B	€13.9B	€9.4B	€6.9B	€10.3B	€10.3B	€9.1B	€7.3B	€8.3B	€6.4B	€1.9B	€5.8B	€689M	€540M	€1.7B	€1.2B
Total Liabilities	€59.5B	€55.1B	€54.9B	€52.1B	€51.6B	€51.2B	€51.2B	€53.4B	€52.4B	€41.6B	€46.9B	€44.1B	€41.1B	€39.0B	€42.9B	€44.3B	€32.0B	€31.6B	€26.9B	€24.3B	€28.5B
Total Debt (Short + Long-Term)	€21.9B	€18.9B	€16.3B	€16.9B	€19.3B	€20.6B	€22.7B	€24.9B	€24.6B	€15.6B	€18.6B	€16.4B	€30.0B	€18.5B	€17.9B	€19.2B	€10.4B	€11.4B	€7.6B	€7.7B	€8.4B
Total Shareholders' Equity	€69.2B	€71.4B	€77.5B	€74.0B	€74.8B	€68.7B	€63.1B	€59.2B	€59.0B	€58.1B	€57.6B	€58.0B	€56.1B	€56.9B	€57.3B	€56.2B	€53.1B	€48.2B	€44.9B	€44.5B	€45.6B

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SNY viewer.

Other Companies in DRUG MANUFACTURERS - GENERAL

NVS · Novartis AG ADR — $267 billion
AZN · AstraZeneca PLC — $258 billion
NVO · Novo Nordisk A/S — $191 billion
GSK · GlaxoSmithKline PLC ADR — $101 billion
GRFS · Grifols SA ADR — $5 billion
OGN · Organon & Co — $4 billion

← SNXX All “S” companies SNYR →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.